Mirtazapine versus paroxetine in panic disorder: an open study

References

• Davidson JRT. Use of benzodiazepines in panic disorder. J Clin Psychiatry 1997; 58: 26–8
   Google Scholar
• Jefferson JW. Antidepressants in panic disorder. J Clin Psychiatry 1997; 58: 20–4
   Google Scholar
• Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: A placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 251–61
   Google Scholar
• Munjack DJ, Usigli R, Zulueta A, Crocker B, Adatia N, Buckwalter JG, Baltazar P, Kurvink W, Inglove H, Kelly R. Nortriptyline in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1998; 8: 204–7
   Google Scholar
• Kalus O, Asnins GM, Rubinson E, Kahn R, Friedman JM, Iqbal N, Grosz D, van Praag H, Cahn W. Desipramine treatment in panic disorder. J Affect Disord 1991; 21: 239–44
   Google Scholar
• Van Vliet IM, Westenberg HG, de Boer JA. MAO inhibitors in panic disorder: cinical effects of treatment with brofaromine. Psychopharmacology 1993; 112: 483–9
   PubMed Web of Science ®Google Scholar
• Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987; 48: 55–9
   PubMed Web of Science ®Google Scholar
• Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis. Int Clin Psychopharmacol 1995; 10: 45–9
   PubMed Web of Science ®Google Scholar
• Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Oshrstrom JK, Manniche PM. Paroxetine in the treatment of panic disorder: A randomized, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167: 374–9
   PubMed Web of Science ®Google Scholar
• Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993; 54: 435–8
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Leon Z, Yasmin S, Price LH. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999; 11: 81–6
   PubMedGoogle Scholar
• Ribeiro L, Busnello JV, Kauer-Sant′Anna M, Madruga M, Quevedo J, Busnello EA, Kapezinski F. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 2001; 34: 1003–7
   Google Scholar
• Boshuisen ML, Slaap BR, Vester-Blockland ED, den Boer JA. The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol 2001; 6: 363–8
   Google Scholar
• Sarchiapone M, Amore M, De Risio S, Cali V, Faia V, Poterzio F, Balista C, Camardese G, Ferrari G. Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol 2003; 18: 35–8
   PubMed Web of Science ®Google Scholar
• Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Noradrenergic neuronal dysregulation in panic disorder: The effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 1992; 86: 273–82
   PubMed Web of Science ®Google Scholar
• Charney DS, Bremner JD. Noradrenergic neural substrates for anxiety and fear: Clinical association based on preclinical research. Psychopharmacology: The Fourth Generation of Progress, F Bloom, D Kupfer. Raven Press, New York 1995; 387–97
   Google Scholar
• Price LH, Goddard AW, Barr L, Goodman WK. Pharmacologic challenges in anxiety disorders. Psychopharmacoly: The Fourth Generation of Progress, FE Bloom, DJ Kupfer. Raven Press, New York 1995; 1311–25
   Google Scholar
• De Boer T, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of de 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988; 27: 399–408
   PubMed Web of Science ®Google Scholar
• Kao L, Barkin RL, Leikin J. Mirtazapine overdose: a case report. Medical Update for Psychiatrists. Elsevier, New York 1997; 22: 58–9
   Google Scholar
• De Boer T., Ruigt GSF. The selective α2-adrenoreceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5-HT1A mediated setotonergic neurotransmission. CNS Drugs 1995; 4(Suppl 1)29–38
   Google Scholar
• Thome J, Henn FA, Duman RS. Cyclic AMP response element-binding protein ans depresión. Expert Rev Neurother 2002; 2: 347–54
   PubMedGoogle Scholar
• Schule C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berlin) 2002; 63: 95–101
   Google Scholar
• Papp LA, Coplan JD, Martinez JM, de Jesus M, Gorman JM. Efficacy of open-label nefazodone treatment in patients with panic disorder. J Clin Psychopharm 2000; 20: 554–6
   Google Scholar
• DeMartinis NA, Schweizer E, Rickels K. An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychopharmacol 1996; 22(1)95–6
   Google Scholar
• Strohle A, Ehrenthal HD. J Clin Psychopharm 2002; 22: 95–6
   Google Scholar
• Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71
   PubMed Web of Science ®Google Scholar
• Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 5: 893–7
   Google Scholar
• Stein MB, Ulm TW. Panic disorder and major depression state of two syndromes. Psychiatr Clin North Am 1988; 11: 441–61
   PubMed Web of Science ®Google Scholar
• Fawcett JA, Kravitz HM. Anxiety syndrome and their relationship to depressive illness. J Clin Psychiatry 1983; 44: 8–11
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Baldwin DS, van Baer JA, Kasper S, Stear MK. Contensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1988; 59: 41–54
   Google Scholar
• Rapaport MH, Pollack M, Wolkow R, Mardethinn J, Clary C. Is placebo response the same as drug response in panic disorder?. Am J Psychiatry 2000; 157: 1014–6
   Google Scholar